The basic structure of the preconditioning regimen consists of fludarabine (FLU) at 30 mg/m2/day for 6 days (days -9 and -4), melphalan (MEL) at 70 mg/ m2/day for 2 days (days -3 and -2), and rabbit a

4 trials

Sponsors

Hyogo College of Medicine

Conditions

hematologic malignancies relapesd/rejected after allogeneic stem cell transplantationhematologic malignancies, bone marrow failure syndrome, and other hematological disorders which requires hematopoietic stem cell transplantaitonhematologic malignancies, bone marrow failure syndrome, and other hematological disorders which requires hematopoietic stem cell transplantation

Phase 1

spousal hematopoietic stem cell transplantation for post-transplant relapse/rejection (phase I/II trial)

RecruitingJPRN-UMIN000023235

Hyogo College of Medicinehematologic malignancies relapesd/rejected after allogeneic stem cell transplantation

Start: 2016-08-01Target: 20Updated: 2026-06-29

Hematopoietic stem cell transplantation from HLA fully mismatched family members for post-transplant relapse/rejection (phase I/II trial)

RecruitingJPRN-UMIN000023548

Hyogo College of Medicinehematologic malignancies relapesd/rejected after allogeneic stem cell transplantation

Start: 2016-08-09Target: 20Updated: 2026-06-29

Phase 2

Hematopietic stem cell transplantation from HLA 2-3 antigen-mismatched family donor using reduced intensity conditioning

JPRN-UMIN000023784

Hyogo College of Medicinehematologic malignancies, bone marrow failure syndrome, and other hematological disorders which requires hematopoietic stem cell transplantaiton

Start: 2016-08-26Target: 100Updated: 2026-06-29

HLA haploidentical hematopoietic stem cell transplantation, Phase II trial

RecruitingJPRN-UMIN000027049

Hyogo College of Medicinehematologic malignancies, bone marrow failure syndrome, and other hematological disorders which requires hematopoietic stem cell transplantation

Start: 2017-04-18Target: 100Updated: 2026-06-29